Microwave-accelerated synthesis of P1′-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1828-1832

  Ekegren, Jenny K ^a   Ginman, Nina ^a   Johansson, Åsa ^a   Wallberg, Hans ^b   Larhed, Mats ^a   Samuelsson, Bertil ^b   Unge, Torsten ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; INDINAVIR; PALLADIUM; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROWAVE RADIATION; NONHUMAN; PROTEINASE INHIBITION; X RAY CRYSTALLOGRAPHY;

ALCOHOLS; BINDING SITES; CATALYSIS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROGEN BONDING; INDANS; MICROWAVES; MOLECULAR MIMICRY; PALLADIUM;

EID: 33644868727     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051239z     Document Type: Article

References (40)

1. Pomerantz, R. J.; Horn, D. L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.
2. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
3. Huff, J. R. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
4. Abdel-Rahman, H. M.; Al-Karamany, G. S.; El-Koussi, N. A.; Youssef, A. F.; Kiso, Y. HIV protease inhibitors: peptidomimetic drugs and future perspectives. Curr. Med. Chem. 2002, 9, 1905-1922.
5. Brik, A.; Wong, C.-H. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 2003, 1, 5-14.
6. Randolph, J. T.; DeGoey, D. A. Peptidomimetic inhibitors of HIV protease. Curr. Top. Med. Chem. 2004, 4, 1079-1095.
7. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
8. Mocroft, A.; Vella, S.; Benfield, T. L.; Chiesi, A.; Miller, V.; Gargalianos, P.; d'Arminio Monforte, A.; Yust, I.; Bruun, J. N.; Phillips, A. N.; Lundgren, J. D. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352, 1725-1730.
9. Thaisrivongs, S.; Romero, D. L.; Tommasi, R. A.; Janakiraman, M. N.; Strohbach, J. W.; Turner, S. R.; Biles, C.; Morge, R. R.; Johnson, P. D.; Aristoff, P. A.; Tomich, P. K.; Lynn, J. C.; Horng, M. M.; Chong, K. T.; Hinshaw, R. R.; Howe, W. J.; Finzel, B. C.; Watenpaugh, K. D. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J. Med. Chem. 1996, 39, 4630-4642.
10. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M.-M.; Lynn, J. C.; Chong, K.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 1998, 41, 3467-3476.
11. Rodríguez-Barrios, F.; Gage, F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr. Top. Med. Chem. 2004, 4, 991-1007.
12. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 1999, 180, 1833-1837.
13. Acosta, E. P.; Kakuda, T. N.; Brundage, R. C.; Anderson, P. L.; Fletcher, C. V. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 2000, 30, S151-S159.
14. Fässler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J.; Poncioni, B.; Rösel, J.; Tintelnot-Blomley, M.; Lang, M. Aza-peptide analogues as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 1996, 39, 3203-3216.
15. Bold, G.; Fässler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hurlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 1998, 41, 3387-3401.
16. Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P.-F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
17. Havlir, D. V.; O'Marro, S. D. Atazanavir: new option for treatment of HIV infection. Clin. Infect. Dis. 2004, 38, 1599-1604.
18. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; et al. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
19. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
20. Ekegren, J. K.; Unge, T.; Safa, M. Z.; Wallberg, H.; Samuelsson, B.; Hallberg, A. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. J. Med. Chem. 2005, 48, 8098-9102.
21. Negishi, E.-i.; Ed. Handbook of Organopalladium Chemistry for Organic Synthesis; Wiley-Interscience: New York, 2002; Volume 1.
22. Larhed, M.; Moberg, C.; Hallberg, A. Microwave-accelerated homogeneous catalysis in organic chemistry. Acc. Chem. Res. 2002, 35, 717-727.
23. Larhed, M.; Hallberg, A. Microwave-assisted high-speed chemistry: a new technique in drug discovery. Drug Discovery Today 2001, 6, 406-416.
24. Ersmark, K.; Larhed, M.; Wannberg, J. Microwave-enhanced medicinal chemistry: A high-speed opportunity for convenient preparation of protease inhibitors. Curr. Opin. Drug Discovery Devel. 2004, 7, 417-427.
25. Savin, V. I. N-Nitrenes. IV. Synthesis of unsymmetrical bibenzyls. Zh. Org. Khim. 1992, 28, 43-50.
26. Otteneder, M.; Plastaras, J. P.; Marnett, L. J. Reaction of malondi-aldehyde-DNA adducts with hydrazines-development of a facile assay for quantification of malondialdehyde equivalents in DNA. Chem. Res. Toxicol. 2002, 15, 312-318.
27. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
28. Espinet, P.; Echavarren, A. M. C-C coupling: The mechanisms of the Stille reaction. Angew. Chem., Int. Ed. 2004, 43, 4704-4734.
29. Sonogashira, K. In Handbook of Organopalladium Chemistry for Organic Synthesis, Volume 1; Negishi, E.-i., Ed.; Wiley-Interscience: New York, 2002, p 493-530.
30. Kappe, C. O.; Dallinger, D. The impact of microwave synthesis on drug discovery. Nat. Rev. Drug Discovery 2006, 5, 51-63.
31. Nöteberg, D.; Schaal, W.; Hamelink, E.; Vrang, L.; Larhed, M. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II. J. Comb. Chem. 2003, 5, 456-464.
32. 0-catalyzed cross-coupling reaction. J. Organomet. Chem. 1993, 460, 127-129.
33. Alterman, M.; Andersson, H. O.; Garg, N.; Ahlsen, G.; Loevgren, S.; Classon, B.; Danielson, U. H.; Kvarnstroem, I.; Vrang, L.; Unge, T.; Samuelsson, B.; Hallberg, A. Design and fast synthesis of C-terminal duplicated potent Ci-symmetric P1/P1′-modified HIV-1 protease inhibitors. J. Med. Chem. 1999, 42, 3835-3844.
34. 2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations. J. Comb. Chem. 2005, 7, 611-617.
35. Balani, S. K.; Arison, B. H.; Mathai, L.; Kauffman, L. R.; Miller, R. R.; Stearns, R. A.; Chen, I. W.; Lin, J. H. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 1995, 23, 266-270.
36. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
37. Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P.-F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
38. Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aube, J.; Borchardt, R. T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug Delivery Rev. 1997, 27, 235-256.
39. Gray, R. A.; Vander Velde, D. G.; Burke, C. J.; Manning, M. C.; Middaugh, C. R.; Borchardt, R. T. Delta-sleep-inducing peptide: Solution conformational studies of a membrane-permeable peptide. Biochemistry 1994, 33, 1323-1331.
40. Conradi, R. A.; Hilgers, A. R.; Burton, P. S.; Hester, J. B. Epithelial cell permeability of a series of peptidic HIV protease inhibitors: aminoterminal substituent effects. J. Drug Target. 1994, 2, 167-171.